PURPOSE: Treatment of malignant melanoma with interferon-alpha has been associated with a variety of side effects ranging from fatigue to depression, and a concomitant impact on quality of life (QOL), in a variety of case reports and cross-sectional clinical trials. Few, if any, studies have been conducted with the express purpose of assessing the longitudinal course of depression, fatigue, and QOL before and during interferon therapy. DESCRIPTION OF STUDY: The current study reports on 16 patients who were assessed at 6 points in time: baseline, post high dose, and 1, 2, 3, and 6 months post high dose treatment with interferon-alpha with the Brief Symptom Inventory, Beck Depression Inventory, Revised Piper Fatigue Scale, and Functional Assessment of Cancer Therapy-Biological Response Modifiers. RESULTS: Results revealed consistent changes from baseline through 6 month assessment. Specifically, increased somatic complaints, depression, and fatigue were observed on the BSI, BDI, and RPFS, respectively. Additional reductions in QOL on the FACT-BRM were also identified. CLINICAL IMPLICATIONS: The findings suggest that IFN has a significant effect on QOL, but that it may be the somatic symptoms of fatigue that contribute to changes on measures of mood. Limiting the amount of fatigue and depression would appear to be significant if individuals are to successfully complete IFN therapy.
PURPOSE: Treatment of malignant melanoma with interferon-alpha has been associated with a variety of side effects ranging from fatigue to depression, and a concomitant impact on quality of life (QOL), in a variety of case reports and cross-sectional clinical trials. Few, if any, studies have been conducted with the express purpose of assessing the longitudinal course of depression, fatigue, and QOL before and during interferon therapy. DESCRIPTION OF STUDY: The current study reports on 16 patients who were assessed at 6 points in time: baseline, post high dose, and 1, 2, 3, and 6 months post high dose treatment with interferon-alpha with the Brief Symptom Inventory, Beck Depression Inventory, Revised Piper Fatigue Scale, and Functional Assessment of Cancer Therapy-Biological Response Modifiers. RESULTS: Results revealed consistent changes from baseline through 6 month assessment. Specifically, increased somatic complaints, depression, and fatigue were observed on the BSI, BDI, and RPFS, respectively. Additional reductions in QOL on the FACT-BRM were also identified. CLINICAL IMPLICATIONS: The findings suggest that IFN has a significant effect on QOL, but that it may be the somatic symptoms of fatigue that contribute to changes on measures of mood. Limiting the amount of fatigue and depression would appear to be significant if individuals are to successfully complete IFN therapy.
Authors: Rachel Isaksson Vogel; Lori G Strayer; Leah Engelman; Heather H Nelson; Anne H Blaes; Kristin E Anderson; DeAnn Lazovich Journal: Qual Life Res Date: 2017-02-27 Impact factor: 4.147
Authors: Fariba Navid; Cynthia E Herzog; John Sandoval; Vinay M Daryani; Clinton F Stewart; Jami Gattuso; Belinda Mandrell; Sean Phipps; Wassim Chemaitilly; April Sykes; Andrew M Davidoff; Barry L Shulkin; Armita Bahrami; Wayne L Furman; Shenghua Mao; Jianrong Wu; Deborah Schiff; Bhaskar Rao; Alberto Pappo Journal: Pediatr Blood Cancer Date: 2016-04-01 Impact factor: 3.167
Authors: Susan A Oliveria; Jennifer L Hay; Alan C Geller; Maureen K Heneghan; Mary S McCabe; Allan C Halpern Journal: J Cancer Surviv Date: 2007-03 Impact factor: 4.442
Authors: Dennis A Revicki; Alfons J M van den Eertwegh; Paul Lorigan; Celeste Lebbe; Gerald Linette; Christian H Ottensmeier; Shima Safikhani; Marianne Messina; Axel Hoos; Samuel Wagner; Srividya Kotapati Journal: Health Qual Life Outcomes Date: 2012-06-13 Impact factor: 3.186